Anticipated $-0.06 EPS for DURECT Corporation (DRRX) on May, 9

April 17, 2018 - By Robert Judd

DURECT Corporation (NASDAQ:DRRX) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 2.04. That’s change of 0.01, from 2017Q3’s 2.05. 9 investors sold all, 16 reduced holdings as DURECT Corporation ratio dropped. 34 rose stakes while 17 funds acquired stakes. Funds hold 64.77 million shares thus 0.77% less from 2017Q3’s 65.27 million shares.
Alliancebernstein Lp accumulated 0% or 21,500 shs. 1,420 were accumulated by Qs Investors Llc. 281,600 were reported by California Pub Employees Retirement System. Regis Mgmt Ltd Liability Corporation, a California-based fund reported 134,250 shs. Vanguard Grp Inc invested in 6.07M shs. Citigroup owns 14,446 shs. First Eagle Investment Mgmt Limited Liability Co, a New York-based fund reported 22.48 million shs. Renaissance Tech Ltd Liability Company has invested 0% of its capital in DURECT Corporation (NASDAQ:DRRX). New York-based Tower Research Cap Limited Com (Trc) has invested 0% in DURECT Corporation (NASDAQ:DRRX). Barclays Public Limited Co owns 24,041 shs. Regions Financial holds 0% of its capital in DURECT Corporation (NASDAQ:DRRX) for 2,000 shs. Citadel Advisors Lc reported 98,397 shs or 0% of all its holdings. Bancorporation Of America De reported 172,217 shs stake. Geode Cap Management Lc, Massachusetts-based fund reported 1.17 million shs. Two Sigma Securities Ltd Limited Liability Company invested in 0% or 44,650 shs.

DURECT Corporation (NASDAQ:DRRX)’s earnings report is anticipated On May, 9., Faxor reports. The earnings per share diference is $0.00 or 0.00 % from last years number. Previous year: $-0.06; Analysts forcast: $-0.06. After $0.05 EPS report last quarter, Wall Street now sees -220.00 % negative EPS growth of DURECT Corporation. On during the last trading session the stock increased $0.07 or 2.87%, reaching $2.51.Currently DURECT Corporation is uptrending after 121.75% change in last April 17, 2017. DRRX has 507,673 shares volume. DRRX outperformed by 110.20% the S&P500.

DURECT Corporation (NASDAQ:DRRX) Ratings Coverage

In total 2 analysts cover Durect (NASDAQ:DRRX). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. 50% are bullish. 4 are the (NASDAQ:DRRX)’s analyst reports since October 20, 2017 according to StockzIntelligence Inc. On Friday, October 20 the firm has “Neutral” rating given by H.C. Wainwright. On Friday, October 20 the firm earned “Hold” rating by Stifel Nicolaus. On Tuesday, March 6 the firm earned “Buy” rating by H.C. Wainwright. On Friday, March 2 the firm earned “Hold” rating by Stifel Nicolaus.

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs.The firm is valued at $384.88 million. The firm offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand.Last it reported negative earnings. The Company’s product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.

DURECT Corporation (NASDAQ:DRRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.